Instrument Inactif

Communiqués CytRx Corporation Nasdaq

Actions

14/05/25	LadRx: Q1 Earnings Snapshot	AQ
14/03/25	Investor Presentation: March 2025	PU
12/03/25	LadRx Corporation, Inc. to Present at the Virtual Life Science Investor Forum March 13th	AQ
13/12/24	Investor Presentation: December 2024	PU
12/12/24	LadRx Planning NDA Submission under 505(b)(2) for Aldoxorubicin and Other Updates	BU
14/11/24	LadRx: Q3 Earnings Snapshot	AQ
09/10/24	LadRx : Proxy Results Form 8 K	PU
14/08/24	LadRx: Q2 Earnings Snapshot	AQ
04/06/24	LadRx and ImmunityBio Mutually Agree to Terminate Aldoxorubicin License	BU
04/06/24	Investor Presentation: June 2024	PU
15/05/24	LadRx: Q1 Earnings Snapshot	AQ
09/01/24	LadRx Issues 2024 Update to Shareholders	BU
14/11/23	LadRx: Q3 Earnings Snapshot	AQ
11/09/23	LadRx : Modification to Rights of Security Holders - Form 8-K	PU
14/08/23	LadRx: Q2 Earnings Snapshot	AQ
15/07/23	Investor Presentation: July 2023	PU
22/06/23	LadRx Completes Non-Dilutive Financing Transaction for up to $11 Million with XOMA Corporation	BU
18/05/23	LadRx Announces Reverse Stock Split Effective as of May 17, 2023	BU
10/05/23	LadRx Announces Reverse Stock Split	BU
27/03/23	LadRx Highlights Patent Issued for Its LADR Technology	BU
15/03/23	LadRx Announces Review of Strategic Alternatives and Provides Corporate Updates	BU
17/11/22	Investor Presentation: November 2022	PU
17/11/22	LadRx Corporation Issues Corporate Update for 3Q22	BU
05/10/22	LadRx Corporation Announces OTCQB Ticker Change to LADX	BU
26/09/22	Investor Presentation: September 2022	PU